Biomea Fusion, Inc. (BMEA)
Nasdaq · Healthcare · Biotechnology
$1.30+2.36%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $94.0M
- 52-week range
- $0.872 – $2.99
- 52-week change
- −52.43%
- EPS (trailing)
- −$0.29
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Net income
- −$61.8M
- Diluted EPS
- −$1.18
From the company’s annual report on SEC EDGAR.
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Headquarters: San Carlos, United States · 37 employees · biomeafusion.com